WP 1732
Alternative Names: WP-1732Latest Information Update: 11 Jun 2024
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Jagiellonian University; Moleculin Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Eye neoplasms; Pancreatic cancer
Most Recent Events
- 09 May 2024 Discontinued - Preclinical for Pancreatic cancer in Australia (IV) before May 2024 (WPD Pharmaceuticals Website, June 2024)
- 09 May 2024 Discontinued - Preclinical for Pancreatic cancer in USA (IV) before May 2024 (WPD Pharmaceuticals Website, June 2024)
- 09 May 2024 Discontinued for Eye neoplasms in USA (IV) before May 2024 (WPD Pharmaceuticals Website, June 2024)